EUVIMEDEUVIMED entdecken
Systematische Übersicht

Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review

Benoît Allignet, Dirk De Ruysscher, Isabelle Martel-Lafay, Waisse Waissi

Cancer Treatment Reviews · 2023

DOI: 10.1016/j.ctrv.2023.102573 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Treatment Reviews, 2023. Verfasst von Benoît Allignet und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Centre Léon Bérard, 28 rue Laennec, 69673 Lyon, France; Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Radiosurgery, Lung Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 86 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In unresectable stage III non-small cell lung cancer (NSCLC), the standard of care for most fit patients is concurrent chemotherapy with normofractionated radiotherapy (NFRT), followed by durvalumab consolidation. Nevertheless, almost half of patients will present locoregional or metastatic intrathoracic relapse. Improving locoregional control thus remains an important objective. For this purpose, stereotactic body radiotherapy (SBRT) may be a relevant treatment modality. We performed a systematic review of the literature that evaluate the efficacy and safety of SBRT in this situation, either instead of or in addition to NFRT. Among 1788 unique reports, 18 met the inclusion criteria. They included 447 patients and were mainly prospective (n = 10, including 5 phase 2 trials). In none, maintenance durvalumab was administered. Most reported SBRT boost after NFRT (n = 8), or definitive tumor and nodal SBRT (n = 7). Median OS varied from 10 to 52 months, due to the heterogeneity of the included populations and according to treatment regimen. The rate of severe side effects was low, with

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungRadiosurgeryLung NeoplasmsHumansProspective StudiesNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Stage IIIStereotactic body radiation therapyUnresectable non-small cell lung cancer

Autor:innen und Institutionen

  • Department of Radiation Oncology, Centre Léon Bérard, 28 rue Laennec, 69673 Lyon, France; Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1294 Lyon, France. El…
  • Department of Radiation Oncology (Maastro), Maastricht University Medical Center, GROW School for Oncology and Developmental Biology, The Netherlands; Department of Radiotherapy, Erasmus University Medical Center, Rotte…
  • Department of Radiation Oncology, Centre Léon Bérard, 28 rue Laennec, 69673 Lyon, France.

Zitieren

APA

Allignet, B., De Ruysscher, D., Martel-Lafay, I., & Waissi, W. (2023). Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2023.102573

Vancouver

Allignet B, De Ruysscher D, Martel-Lafay I, Waissi W. Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review. Cancer Treatment Reviews. 2023. doi:10.1016/j.ctrv.2023.102573

BibTeX
@article{Allignet2023,
  author = {Allignet, Benoît and De Ruysscher, Dirk and Martel-Lafay, Isabelle and Waissi, Waisse},
  title = {Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review},
  journal = {Cancer Treatment Reviews},
  year = {2023},
  doi = {10.1016/j.ctrv.2023.102573}
}
Kostenlos starten →